503A patient-specific compounding continues under narrower exceptions
Compromised autophagy and neurodegenerative diseases
Animal and clinical studies have shown that GLP-1RAs ameliorate liver inflammation and lower the risk of NAFLD and NASH developing into liver cancer
Rowbottom, L., Stinson, J., McDonald, R., Emmenegger, U., Cheng, S., Lowe, J., Giotis, A., Cheon, P., Chow, R., Pasetka, M., et al
GLP-1 Medications with a simple generic name of "semaglutide", "liraglutide", "tirzepatide", "dulaglutide", "exenatide", "exenatide microspheres", or "insulin degludec/liraglutide" and at least one of: A pharmaceutical class of "ANTI-OBESITY GLUCAGON-LIKE PEPTIDE-1 RECEP AGONIST" or "ANTIHYPERGLYCEMIC - INCRETIN MIMETICS COMBINATION" A pharmaceutical class that contains "GLP-1" A pharmaceutical subclass that contains the text "GLP-1"